NBSE - NeuBase Therapeutics GAAP EPS of -$0.26 beats by $0.04
- NeuBase Therapeutics press release ( NASDAQ: NBSE ): Q3 GAAP EPS of -$0.26 beats by $0.04 .
- As of June 30, 2022, the Company had cash and cash equivalents of approximately $29.8 million, compared with approximately $52.9 million as of September 30, 2021.
For further details see:
NeuBase Therapeutics GAAP EPS of -$0.26 beats by $0.04